Alto Ingredients, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
ALTO$3.74+1.9%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024
CONSOLIDATED BALANCE SHEETS
(in thousands)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | * | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $32,516 | $35,469 |
| Restricted cash | 623 | 742 |
| Accounts receivable (net of allowance for credit losses of $19 and $23, respectively) | 54,757 | 58,217 |
| Inventories | 53,390 | 49,914 |
| Derivative instruments | 3,602 | 3,313 |
| Other current assets | 6,035 | 5,463 |
| Total current assets | 150,923 | 153,118 |
| Property and equipment, net | 203,528 | 214,742 |
| Other Assets: | ||
| Right of use operating lease assets, net | 18,001 | 20,553 |
| Intangible assets, net | 7,730 | 4,509 |
| Other assets | 8,292 | 8,516 |
| Total other assets | 34,023 | 33,578 |
| Total Assets | $388,474 | $401,438 |
| * | Amounts derived from the audited consolidated financial statements for the year ended December 31, 2024. |
|---|
CONSOLIDATED BALANCE SHEETS (CONTINUED)
(in thousands, except par value)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | * | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $15,521 | $20,369 |
| Accrued liabilities | 16,191 | 24,214 |
| Current portion – operating leases | 5,140 | 4,851 |
| Derivative instruments | 108 | 1,177 |
| Other current liabilities | 5,459 | 7,193 |
| Total current liabilities | 42,419 | 57,804 |
| Long-term debt, net | 100,598 | 92,904 |
| Operating leases, net of current portion | 13,955 | 16,913 |
| Other liabilities | 9,100 | 8,754 |
| Total Liabilities | 166,072 | 176,375 |
| Commitments and Contingencies (Note 6) | ||
| Stockholders’ Equity: | ||
| Preferred stock, $0.001 par value; 10,000 shares authorized; Series A: 1,684 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024; Series B: 1,581 shares authorized; 927 shares issued and outstanding as of September 30, 2025 and December 31, 2024; liquidation preference of $18,075 as of September 30, 2025 | 1 | 1 |
| Common stock, $0.001 par value; 300,000 shares authorized; 77,342 and 76,565 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 77 | 77 |
| Non-voting common stock, $0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 1,050,929 | 1,044,176 |
| Accumulated other comprehensive income | 4,975 | 4,975 |
| Accumulated deficit | (833,580) | (824,166) |
| Total Stockholders’ Equity | 222,402 | 225,063 |
| Total Liabilities and Stockholders’ Equity | $388,474 | $401,438 |
| * | Amounts derived from the audited consolidated financial statements for the year ended December 31, 2024. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.